$ALLR
Allarity Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924035314 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.589M $2.313M
YoY Change -35.93% -24.19%
% of Gross Profit
Research & Development $1.021M $1.058M
YoY Change -47.59% -4.25%
% of Gross Profit
Depreciation & Amortization $5.000K $1.000K
YoY Change -50.0% -88.89%
% of Gross Profit
Operating Expenses $12.31M $3.371M
YoY Change 178.2% -18.89%
Operating Profit -$12.31M -$3.371M
YoY Change 178.2% -18.89%
Interest Expense $346.0K $1.742M
YoY Change 917.65% 1126.76%
% of Operating Profit
Other Income/Expense, Net $346.0K $1.742M
YoY Change -1747.62% -1.91%
Pretax Income -$11.97M -$1.629M
YoY Change 168.92% -31.55%
Income Tax -$377.0K
% Of Pretax Income
Net Earnings -$11.59M -$1.629M
YoY Change 160.63% -31.55%
Net Earnings / Revenue
Basic Earnings Per Share -$7.71 -$0.11
Diluted Earnings Per Share -$7.71 -$0.11
COMMON SHARES
Basic Shares Outstanding 4.434M 42.38M shares 17.61M shares
Diluted Shares Outstanding 14.98M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $18.50M $19.23M
Short-Term Investments
Other Short-Term Assets $100.0K $131.0K
YoY Change -90.28% -91.24%
Inventory
Prepaid Expenses $151.0K $366.0K
Receivables
Other Receivables
Total Short-Term Assets $20.37M $21.31M
YoY Change 364.24% 478.11%
LONG-TERM ASSETS
Property, Plant & Equipment $12.00K $17.00K
YoY Change -58.62% -34.62%
Goodwill
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $12.00K $9.574M
YoY Change -99.87% -1.7%
TOTAL ASSETS
Total Short-Term Assets $20.37M $21.31M
Total Long-Term Assets $12.00K $9.574M
Total Assets $20.38M $30.88M
YoY Change 46.87% 130.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.693M $7.753M
YoY Change -26.06% -4.15%
Accrued Expenses $1.322M $1.465M
YoY Change -10.98% -23.74%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.414M $10.62M
YoY Change -52.91% -16.2%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.414M $10.62M
Total Long-Term Liabilities
Total Liabilities $7.414M $11.05M
YoY Change -57.03% -21.92%
SHAREHOLDERS EQUITY
Retained Earnings -$111.5M -$99.90M
YoY Change 20.24% 13.16%
Common Stock $0.00 $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.96M $19.84M
YoY Change
Total Liabilities & Shareholders Equity $20.38M $30.88M
YoY Change 46.87% 130.02%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$11.59M -$1.629M
YoY Change 160.63% -31.55%
Depreciation, Depletion And Amortization $5.000K $1.000K
YoY Change -50.0% -88.89%
Cash From Operating Activities -$5.443M -$7.216M
YoY Change 1.36% 189.1%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.868M 26.31M
YoY Change -24.53% 818.29%
NET CHANGE
Cash From Operating Activities -5.443M -7.216M
Cash From Investing Activities
Cash From Financing Activities 4.868M 26.31M
Net Change In Cash -575.0K 19.09M
YoY Change -153.24% 5074.25%
FREE CASH FLOW
Cash From Operating Activities -$5.443M -$7.216M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001860657
dei Entity Registrant Name
EntityRegistrantName
Allarity Therapeutics, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 allr Preferred Stock Shares Designated
PreferredStockSharesDesignated
500000
CY2023Q4 allr Preferred Stock Shares Designated
PreferredStockSharesDesignated
20000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1417
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1417
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2759070
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2759070
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9812
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9812
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41160
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2147982
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02108
dei City Area Code
CityAreaCode
401
dei Local Phone Number
LocalPhoneNumber
426-4664
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ALLR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4433587
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18463000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
166000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
100000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
209000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
151000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
781000 usd
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1652000 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
815000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
20366000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1971000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9871000 usd
CY2024Q3 us-gaap Assets
Assets
20378000 usd
CY2023Q4 us-gaap Assets
Assets
11862000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4693000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8416000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1309000 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2000 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3083000 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
60000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
59000 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1337000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1300000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7414000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14167000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
446000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
7414000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
14613000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1742000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125170000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
90369000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-693000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-411000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111513000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94451000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12964000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2751000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20378000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11862000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1021000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1948000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4249000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4480000 usd
CY2024Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
9703000 usd
CY2023Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
9703000 usd
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1589000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2478000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5972000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7770000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12313000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4426000 usd
us-gaap Operating Expenses
OperatingExpenses
19924000 usd
us-gaap Operating Expenses
OperatingExpenses
12250000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12313000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4426000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19924000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12250000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
261000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
314000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
19000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
50000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
34000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
578000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
268000 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
121000 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-156000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
69000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-87000 usd
CY2024Q3 allr Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
-14000 usd
CY2023Q3 allr Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
-4937000 usd
allr Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
-2676000 usd
allr Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
-7187000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
346000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2481000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2071000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11967000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4447000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17443000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10179000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-377000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-381000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11590000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4447000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17062000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10179000 usd
CY2024Q3 allr Gain Loss On Extinguishment Of Convertible Preferred Stock
GainLossOnExtinguishmentOfConvertiblePreferredStock
0 usd
CY2023Q3 allr Gain Loss On Extinguishment Of Convertible Preferred Stock
GainLossOnExtinguishmentOfConvertiblePreferredStock
0 usd
allr Gain Loss On Extinguishment Of Convertible Preferred Stock
GainLossOnExtinguishmentOfConvertiblePreferredStock
222000 usd
allr Gain Loss On Extinguishment Of Convertible Preferred Stock
GainLossOnExtinguishmentOfConvertiblePreferredStock
0 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12152000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5552000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17701000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18694000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.71
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1346.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11630.75
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1575762
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4125
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
698877
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1607
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11590000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4447000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17062000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10179000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-163000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-92000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-282000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-37000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11753000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4539000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17344000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10216000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-113000 usd
CY2023Q1 allr Apic Sharebased Payment Arrangement Increase For Cost Recognition Recovery
ApicSharebasedPaymentArrangementIncreaseForCostRecognitionRecovery
-121000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
84000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3352000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3102000 usd
CY2023Q2 allr Series A Redemption Rights Eliminated Value
SeriesARedemptionRightsEliminatedValue
624000 usd
CY2023Q2 allr Apic Sharebased Payment Arrangement Increase For Cost Recognition Recovery
ApicSharebasedPaymentArrangementIncreaseForCostRecognitionRecovery
180000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-29000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-723000 usd
CY2023Q3 allr Redemption Of Preferred Stock Value
RedemptionOfPreferredStockValue
-5000000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
2
CY2023Q3 allr Apic Sharebased Payment Arrangement Increase For Cost Recognition Recovery
ApicSharebasedPaymentArrangementIncreaseForCostRecognitionRecovery
124000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-92000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4447000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3379000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2751000 usd
CY2024Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-0 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40000 usd
CY2024Q1 allr Apic Sharebased Payment Arrangement Increase For Cost Recognition Recovery
ApicSharebasedPaymentArrangementIncreaseForCostRecognitionRecovery
-32000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-25000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3843000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-6471000 usd
CY2024Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-0 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27652000 usd
CY2024Q2 allr Apic Sharebased Payment Arrangement Increase For Cost Recognition Recovery
ApicSharebasedPaymentArrangementIncreaseForCostRecognitionRecovery
22000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
144000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1629000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
19835000 usd
CY2024Q3 allr Redemption Of Preferred Stock Value
RedemptionOfPreferredStockValue
-3500000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-0 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5427000 usd
CY2024Q3 allr Apic Sharebased Payment Arrangement Increase For Cost Recognition Recovery
ApicSharebasedPaymentArrangementIncreaseForCostRecognitionRecovery
17000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
163000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11590000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12964000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17062000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10179000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
28000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
183000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
9703000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
10000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-88000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1110000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
173000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
230000 usd
allr Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
-2676000 usd
allr Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
-7187000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-446000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-109000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-530000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
837000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
774000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-630000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-195000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3623000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
96000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-123000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-152000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-13000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-8000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14146000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11073000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33119000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
16895000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1720000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1340000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1050000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1340000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3698000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32557000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10473000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18411000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-600000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-114000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-30000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
166000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2029000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18463000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1399000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000 usd
us-gaap Interest Paid Net
InterestPaidNet
408000 usd
us-gaap Interest Paid Net
InterestPaidNet
36000 usd
us-gaap Stock Issued1
StockIssued1
90000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
allr Stock Issued From Conversion Of Warrants
StockIssuedFromConversionOfWarrants
405000 usd
allr Stock Issued From Conversion Of Warrants
StockIssuedFromConversionOfWarrants
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111500000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18500000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-200000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-100000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-300000 usd
us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-37000000000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentrations of credit risk and of significant suppliers</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 16pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents in financial institutions in amounts that could exceed government-insured limits. The Company does <em style="font: inherit;">not</em> believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has <em style="font: inherit;">not</em> experienced losses on its cash and cash equivalents accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is <em style="font: inherit;">not</em> significant. The Company is dependent on <em style="font: inherit;">third</em>-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
9800000 usd
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
9700000 usd
CY2024Q3 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
100000 usd
CY2024Q3 allr Accrued Development Cost Liability
AccruedDevelopmentCostLiability
105000 usd
CY2023Q4 allr Accrued Development Cost Liability
AccruedDevelopmentCostLiability
114000 usd
CY2024Q3 allr Accrued Interest On Milestone Liabilities
AccruedInterestOnMilestoneLiabilities
237000 usd
CY2023Q4 allr Accrued Interest On Milestone Liabilities
AccruedInterestOnMilestoneLiabilities
101000 usd
CY2024Q3 allr Accrued Audit And Legal
AccruedAuditAndLegal
652000 usd
CY2023Q4 allr Accrued Audit And Legal
AccruedAuditAndLegal
425000 usd
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
233000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
398000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
95000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
271000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1309000 usd
CY2024Q2 us-gaap Share Price
SharePrice
34.5
CY2024Q3 allr Common And Preferred Stock Shares Authorized
CommonAndPreferredStockSharesAuthorized
750500000
CY2024Q3 allr Common And Preferred Stock Shares Authorized
CommonAndPreferredStockSharesAuthorized
250500000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
228487
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 allr Equity Offering Amount Available
EquityOfferingAmountAvailable
15900000 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
353163
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
72278
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
353163
CY2024Q3 allr Sharebased Compensation Arrangement By Sharebased Payment Award Annual Percentage Increase
SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncrease
0.05 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
353156
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4725600
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2606960
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
7
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
924000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5328373
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y7M6D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
180000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59000 usd
CY2024Q2 allr Milestone Payment Sales
MilestonePaymentSales
50000000 usd
CY2024Q2 allr Licensed Product Sales
LicensedProductSales
1000000000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
182602
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29929

Files In Submission

Name View Source Status
0001437749-24-035314-index-headers.html Edgar Link pending
0001437749-24-035314-index.html Edgar Link pending
0001437749-24-035314.txt Edgar Link pending
0001437749-24-035314-xbrl.zip Edgar Link pending
allr-20240930.xsd Edgar Link pending
allr20240930_10q.htm Edgar Link pending
ex_729176.htm Edgar Link pending
ex_729177.htm Edgar Link pending
ex_729178.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
allr-20240930_def.xml Edgar Link unprocessable
allr-20240930_lab.xml Edgar Link unprocessable
allr-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
allr20240930_10q_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
allr-20240930_cal.xml Edgar Link unprocessable